CARLSBAD, Calif., Dec. 10, 2012 /PRNewswire-iReach/ -- RiboMed Biotechnologies Inc., a leading Epigenetics-Based Diagnostics company, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for three additional patents covering the use of their core technology, Abscription® (Abortive Transcription), for disease and biowarfare agent related biomarker detection. The patents expand protection to MethylMagnet® and MethylMeter®, RiboMed's bisulfite-free DNA methylation detection products and assays, including a new prognostic test for brain cancer, G-CIMP DecisionDx.
"These patent issuances further solidify RiboMed's position in clinical diagnostics, particularly in the use of DNA Methylation biomarkers for cancer detection, staging and drug development" stated Dr. Michelle Hanna, Chief Executive Officer and Scientific Director of RiboMed. "The technologies protected by these patents make DNA methylation profiling possible even on formalin fixed paraffin embedded (FFPE) tumor tissues, as we have shown with the G-CIMP DecisionDx test launched in RiboMed's CLIA laboratory earlier this year in partnership with Castle Biosciences." G-CIMP stands for Glioma specific CpG Island Methylator Phenotype, and the test predicts the aggressiveness of certain brain tumors, providing physicians and patients with a new tool for making treatment decisions.
The claims of U.S. Patent 8,263,339, entitled "Abscription based molecular detection" broadly cover RiboMed's core Abscription technology for use in detecting a wide variety of molecular biomarkers, including DNA, RNA, protein and methylated DNA. Detection tests reduced to practice in addition to those for DNA methylation include sensitive and robust assays for Salmonella (DNA), viral RNAs and toxic proteins, such as ricin, Botulinum toxin and the common food poisoning agent, SEB. These assays were developed with the Depar
|SOURCE RiboMed Biotechnologies, Inc.|
Copyright©2012 PR Newswire.
All rights reserved